| Study Name | Description | Trial Category | Trial SubCategory |
|---|---|---|---|
| A032302 | This study aims to determine if the addition of docetaxel to androgen deprivation therapy and apalutamide improves overall survival for men with metastatic castrate senstive prostate cancer. The study will also examine the subset of men whose cancers have loss or inactivating mutations of TP53, PTEN, or RB1. | Baby/Child | Prostate |
| A042302 | This study will compare progression-free survival between MRD-guided post-induction treatment strategy following zanubrutinib plus sonrotoclax therapy to continuous zanubrutinib as control. | Cancer | Hematology |
| A052101 | The study aims to compare survival between continuous treatment versus intermittent treatment that is restarted at first progression. | Cancer | Lymphoma |
| EA8231 | The goal of the study is to evaluate progression free survival between the Therapy per Physician Choice (TPC) versus Sacituzumab + Pembrolizumab regimen. Follow-up period of 5 years from the date of randomization. | Cancer | Bladder - Urothelial |
| NRG-GU014 | The goal of the study is to compare the survival of bladder-intact patients receiving a combination of radiation therapy and pembrolizumab or radiation therapy and chemotherapy. | Cancer | Bladder - Urothelial |
| S2005 | The study goal is to compare the rate of very good partial response or better in previously untreated participants with Waldenstrom's Macroglobulinemia (WM)/Lymphoplasmacytic Lymphoma (LPL) who are treated upfront with ibrutinib + rituximab or zanubrutinib alone versus venetoclax + rituximab regimen. | Cancer | Hematology |
| Azalea OLE | A multicenter, randomized, active-controlled study to evaluate the safety and Tolerability of two blinded doses of Apelacimab (MAA868) compared with open-label Rivaroxaban in patients with Atrial Fibrillation. | Heart & Vascular | Atrial Fibrillation |
| Remedy Spectrum | A prospective, multi-center study to evaluate the safety and effectiveness of the Remedy Spectrum GV IM Spacer Nail in the treatment of ankle-related infections. | Orthopedics | Infection |
| V-Intervention | Evaluation of inclisiran versus placebo for the prevention of major adverse cardiovascular and limb events in patients undergoing percutaneous coronary intervention or peripheral endovascular intervention. | Heart & Vascular | Cardiovascular Disease |
| VYKAT XR | Prospective observational study developed to generate more evidence of the safety profile, clinical characteristics and outcomes of patients with PWS treated with VYKAT XR. | Endocrinology | Genetic Disorder |
| A232402CD | To compare the proportion of chemotherapy cycles with unplanned delays in patients receiving FOLFOX chemotherapy under standardized usual care (control) vs according to the PAGODA dose modification algorithm (intervention). | Cancer | Gastrointestinal |
| NRG-CC015 | This study will evaluate the efficacy of two distinct digital approaches for delivering a mindfulness-based intervention: a live, instructor-led version delivered over Zoom (MAPs LO), and an app-based, self-paced version (MAPs App). Participants will include younger breast cancer survivors (BCS) who were diagnosed with breast cancer at or before age 50 years, have completed their primary cancer treatment (i.e., surgery, radiation, and/or chemotherapy) at least 6 months earlier, and report elevated depressive symptoms. | Cancer | Breast |
| S2409 | This trial tests how well biomarker tests on patients tumor tissue works in selecting personalized treatments for patients with extensive stage small cell lung cancer (ES-SCLC). Biomarker tests look for certain features in cancer cells that may give doctors more information about what is driving cancer and how to treat it. Based on the biomarker test results, study doctors can determine the subtype of ES-SCLC that study treatments can target. | Cancer | Small Cell Lung |
| A012103 | This study will investigate whether adjuvant checkpoint inhibition offers any additional recurrence-free survival (RFS) benefit to early-stage Triple Negative Breast Cancer patients who achieve a pathologic Complete Response (pCR) after neoadjuvant chemotherapy with checkpoint inhibition. If there is no significant difference in RFS, then patients who achieve a pCR can avoid the additional toxicity, inconvenience, and cost of continued ICI treatment. | Cancer | Breast |
| A012303 | This trial will answer the question of whether, for patients classified as low risk based on pathologic Complete Response (pCR) following neoadjuvant therapy, 6 months of overall HER2 blockade is an acceptable duration (compared to 12 months). | Cancer | Breast |
| BACKBEAT Study | The purpose of this study is to evaluate the effectiveness and safety of a new pacemaker program called Atrioventricular Interval Modulation (AVIM) in patients who are schedule to have, or recently received, a pacemaker. | Heart & Vascular | Hypertension |
| A032201 | This study compares the addition of tivozanib to standard therapy pembrolizumab versus pembrolizumab alone for the treatment of patients with high-risk renal cell carcinoma (RCC). | Cancer | Renal |
| A092205 | This study compares the efficacy of cetuximab and pembrolizumab versus pembrolizumab alone in the treatment of recurrent and/or metatstatic head and neck squamous cell carcinoma. | Cancer | Head & Neck |
| EA5162 | This study aims to evaluate the safety and efficacy of osimertinib (AZD9291) among patients with non-small cell lung cancer with EGFR exon 20 insertions. | Cancer | Lung |
| NRG-GI011 | This study evaluates the overall survival rate of advanced pancreatic cancer patients who pursue dose-escalated radiation therapy versus standard treatment without dose-escalated radiation therapy at 3 years. | Cancer | Pancreatic |
| S1800E (LUNGMAP substudy) | This study is comparing a regimen of Docetaxel and Ramucirumab with or without Cemiplimab for participants with recurrent Non-Small Cell Lung Cancer, previously treated with platinum-basesd chemotherapy and immunotherapy. | Cancer | Non-Small Cell Lung |
| S1931 | This study evaluates adding surgery (radical or partial nephrectomy) to standard immunotherapy-based drug treatments for patients with metastatic renal cancer. | Cancer | Metastatic Renal |
| S2414 | This study compares disease free survival rate in patients treated with durvalumab after surgery versus observation only with early-stage non-small cell lung cancer. | Cancer | Non-Small Cell Lung |
| Easi-HF Preserved | The purpose of this study is to evaluate efficacy and safety of the combined use of oral Vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) >= to 40% | Heart & Vascular | Atrial Fibrillation |
| QDOT | The purpose of this study is to evaluate the long-term safety and effectiveness of the QDOT Micro system use in conjunction with Visitag Surpoint Module for the treatment of symptomatic drug refractory Paroxysmal Atrial Fibrillation. | Heart & Vascular | Atrial Fibrillation |
| SOS Maternity | This purpose of this study is to provide interventions to reduce the rate of preeclampsia and preterm birth across Michigan's health care systems. | OB/GYN | Obstetrics (OB) |
| Vanquish 2 | This is a study to evaluate the efficacy and safety of VK2735, administered subcutaneously, for weight management in adults with Type 2 Diabetes. | Diabetes | Obesity and Type 2 Diabetes |
| A072201 | This study if for patients with recurrent glioblastomas. It is looking at standard of care treatment (Lomustine) vs Anti-LAG-3 and Anti-PD-L1 Blockade. | Cancer | Glioblastoma |
| NRG GU013 | This study is for patients with high risk prostate cancer. PSA must be >20 ng/ml. Patient must have a Gleason score of 8-10. Patient cannot have metastatic disease outside of pelvic lymph nodes. No prior radiation or androgen deprivation therapy allowed. | Cancer | Prostate |
| NRG-GU011 | The purpose of this study is to look at adding Androgen deprivation therapy in patients with prostate cancer with only a few areas of metastasis. You must have had prior curative intent treatment to the prostate. | Cancer | Prostate |
Unsupported Browser! This website will offer limited functionality in this browser. We only support the recent versions of major browsers like Chrome, Firefox, Safari, and Edge.